Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarXT With Prophylactic and PRN Antiemetic Use in Healthy Volunteers
NCT07681076Phase 4Recruiting
- Sponsor
- Karuna Therapeutics
- Start
- Sep 2026
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of xanomeline in schizophrenia (4 arms), sponsored by Karuna Therapeutics. Primary endpoint: Treatment Emergent Adverse Events at 21 days. Started Sep 2026; status: recruiting.
02
Drugs
xanomeline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07681076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07681076.